IL4 and Parkinson disease: In addition, in mitochondrial toxin models of PD, the complex 1 inhibitor rotenone could prevent the protective effects of IL-4 treatment in vitro [117,118] suggesting therapeutic benefit of IL-4 may be limited in the pathological context of PD.